Search

Displaying results 3691 - 3700 of 3888 in total
  1. Drug

    Relutrigine

    go.drugbank.com/drugs/DB21614
    Investigational

    The usage of the INN stem '-trigine' in the name indicates that Relutrigine is a sodium channel blocker, signal transduction modulator.

  2. Drug

    Foselutoclax

    go.drugbank.com/drugs/DB21663
    Investigational

    The usage of the INN stem '-toclax' in the name indicates that Foselutoclax is a B-cell lymphoma 2 (Bcl-2) inhibitor.

  3. Drug

    Promegestone

    go.drugbank.com/drugs/DB13602
    Experimental

    Categories: Genito Urinary System and Sex Hormones, Sex Hormones and Modulators of the Genital System
  4. Drug

    Plosaracetam

    go.drugbank.com/drugs/DB21594
    Investigational

    The usage of the INN stem '-racetam' in the name indicates that Plosaracetam is a piracetam type amide type nootrope agent.

  5. Drug

    Icalcaprant

    go.drugbank.com/drugs/DB21651
    Investigational

    The usage of the INN stem '-caprant' in the name indicates that Icalcaprant is a kappa-opioid receptor (KOR) antagonist.

  6. Drug

    Olomorasib

    go.drugbank.com/drugs/DB21697
    Investigational

    The usage of the INN stem '-rasib' in the name indicates that Olomorasib is a Ras protein inhibitor.

  7. Drug

    Istisociclib

    go.drugbank.com/drugs/DB21703
    Investigational

    The usage of the INN stem '-ciclib' in the name indicates that Istisociclib is a cyclin dependant kinase inhibitor.

  8. Drug

    Atirmociclib

    go.drugbank.com/drugs/DB21733
    Investigational

    The usage of the INN stem '-ciclib' in the name indicates that Atirmociclib is a cyclin dependant kinase inhibitor.

  9. Drug

    Succinimide

    go.drugbank.com/drugs/DB13376
    Experimental

    Categories: Genito Urinary System and Sex Hormones
  10. Drug

    Turoctocog alfa pegol

    go.drugbank.com/drugs/DB14738
    ApprovedInvestigational

    Turoctocog alfa pegol is a pegylated version of turoctocog alfa. Novo Nordisk's brand name Esperoct (turoctocog alfa pegol, N8-GP) was approved by the US FDA on February 19, 2019. Fundamentally, the N8-GP moiety is identical to turoctoco...